Distinct Features of Vascular Diseases in COVID-19

Abstract

The Coronavirus Disease 2019 (COVID-19) pandemic was declared in early 2020 after several unexplained pneumonia cases were first reported in Wuhan, China, and subsequently in other parts of the world. Commonly, the disease comprises several clinical features, including high temperature, dry cough, shortness of breath, and hypoxia, associated with findings of interstitial pneumonia on chest X-ray and computer tomography. Nevertheless, severe forms of acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) are not limited to the respiratory tract but also may be extended to other systems, including the cardiovascular system. The bi-directional relationship between atherosclerosis and COVID-19 is accompanied by poor prognosis. The immune response hyperactivation due to SARS-CoV-2 infection causes an increased secretion of cytokines, endothelial dysfunction, and arterial stiffness, which promotes the development of atherosclerosis. Also, due to the COVID-19 pandemic, access to healthcare amenities was reduced, resulting in increased morbidity and mortality in patients at risk. Furthermore, as lockdown measures were largely adopted worldwide, the sedentary lifestyle and the increased consumption of processed nutrients or unhealthy food increased, and in the consequence, we might observe even 70% of overweight and obese population. Altogether, with the relatively low ratio of vaccinated people in many countries, and important health debt appeared, which is now and will be for next decade a large healthcare challenge. However, the experience gained in the COVID-19 pandemic and the new methods of patients’ approaching have helped the medical system to overcome this crisis and will hopefully help in the case of new possible epidemics.

Introduction

The Coronavirus Disease 2019 (COVID-19) pandemic was declared in early 2020 after several unexplained pneumonia cases were first reported in Wuhan, China, and subsequently in other parts of the world. Commonly, the disease comprises several clinical features, including high temperature, dry cough, shortness of breath, and hypoxia, associated with findings of interstitial pneumonia on chest X-ray and computer tomography.^1–3 This disease requires specific treatment, which directly depends on the COVID-19 severity.^4–6 Nevertheless, severe forms of acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) are not limited to the respiratory tract but also may be extended to other systems, including the cardiovascular system.^7–11

Therefore, the aim of the current review is to summarize the effects of SARS-CoV-2 infection on the initiation and progression of atherosclerotic diseases and the pathophysio-logical mechanisms involved.

Pathophysiological Mechanisms That Drive COVID-19 Related Vascular Diseases

Endothelial Dysfunction

The vascular endothelium consists of endothelial cells that act as a semipermeable barrier by forming the inner cellular lining of blood vessels. The endothelium is essential for maintaining vascular health and hemostasis, as it inhibits clot formation and restores vascular homeostasis.¹² It synthesizes nitric oxide (among other vasoactive substances), which protects against atherosclerosis, causes vasodilation by acting on vascular smooth muscles, and regulates thrombus formation and fibrinolysis.^13,14

Endothelium that fails to function appropriately is associated with the vast majority of cardiovascular conditions and is characterized by the loss of vascular integrity, a pro-thrombotic and proinflammatory phenotype and reduced vasodilation.^15–17 Factors that promote endothelial dysfunction include smoking, metabolic disorders, chronic illnesses, and disturbed blood flow.^18,19

In clinically severe infections, endothelial dysfunction can be elicited directly through signaling effects of the virus or indirectly by maladaptation of the immuno-logical response leading to inappropriate endothelial activation. This particular state of endothelial dysfunction caused by viral infections predisposes to coagulopathies and it is characterized by vascular leakage. The excess of free radicals disrupts the semipermeable barrier reducing nitric oxide release, which in turn promotes vasoconstriction and allows penetration of toxins into the underlying tissues. Previous coronavirus infections have been documented to cause indirect endothelial dysfunction through elevated proinflammatory mediators leading to coagulopathies. Likewise, COVID-19 appears to reproduce a similar prothrombotic effect.¹²

Autopsy reports indicate that the histologic pattern in the peripheral lung was diffuse alveolar damage with perivascular T-cell infiltration. The lungs of patients with COVID-19 also showed distinctive vascular features, consisting of severe endothelial injury associated with the presence of intracellular viruses and disrupted cell membranes. Histologic analysis of pulmonary vessels in patients with COVID-19 showed widespread thrombosis with microangiopathy. Alveolar capillary microthrombi were 9 times as prevalent in patients with COVID-19 as in patients with influenza.²⁰

It is presumed that the primary entry and infection mechanism of SARS-CoV-2 is via angiotensin-converting enzyme 2 (ACE2) receptors, which are expressed in the respiratory and vascular endothelium, among other cells.²¹ The injury of endothelial cells, and subsequent endothelial dysfunction, is initiated by the attachment of the pathogen to the ACE2 receptor.²² SARS-CoV-2 can affect any organ expressing ACE2 receptors and downregulates its expression on the cell surface.²³ The primary role of ACE2 is cardioprotective by converting angiotensin I and angiotensin II into angiotensin 1–9 and angiotensin 1–7, respectively. Loss of ACE2 on vascular endothelium can therefore exacerbate inflammation, thrombosis, and endothelial dysfunction.^24,25 Damage to the endothelial cells might also be directly triggered by the infection, resulting in reduced nitric oxide (NO) availability, oxidative stress and inflammation (Figure 1).²⁶

Figure 1.

Endothelial dysfunction and vascular inflammation caused by SARS-CoV-2 infection. Circulating SARS-CoV-2 virus induces a systemic inflammatory response, but it can also be taken up by endothelial cells (ECs), likely via binding to the ACE2 receptor. Inside the cell, the viral RNA is recognized by pattern recognition receptors, such as Toll like receptors (TLRs) and generates an inflammatory response through upregulation of NF-κB. In addition, the binding of virus to the ACE2 receptor results in a shift towards increased angiotensin II (AngII)-angiotensin II type 1 (AT1) receptor signalling, which further enhances the production of inflammatory cytokines via the NF-κB pathway. This will lead to increased levels of reactive oxygen species (ROS) and a lower nitric oxide (NO) bioavailability, consequently enabling endothelial dysfunction and stimulating apoptotic cell death. Furthermore, glycocalyx degrading enzymes will give rise to shedding of glycocalyx fragments, tight junctions will be disrupted and together with the increased expression of adhesion molecules, leukocyte recruitment and extravasation are promoted. The upregulation of P-selectin, fibrinogen, von Willebrand factor (vWF) and tissue factor will contribute to platelet aggregation and coagulation, potentially giving rise to thrombotic complications. (Created with BioRender.com).

In addition, COVID-19 induces a specific proinflammatory state, called a “cytokine storm”. This is an excessive release of cytokines that has been observed in severe forms of the disease, further promoting vascular inflammation, endothelial dysfunction, coagulation disorders, and cardiovascular complications. However, it is still under debate whether the inflammatory-associated changes are a direct effect of COVID-19 or a consequence of the “cytokine storm”.^27,28

Among COVID-19 patients, reduced levels of NO are observed. The underlying pathological manifestations in severe clinical cases are endothelial dysfunction, coagulopathy, inflammation, and vascular leakage. Increased platelet activation, high levels of fibrinogen and D-dimers in the plasma have also been observed in severe cases of COVID-19. Especially, elevated D-dimer levels are associated with a poor prognosis.²⁹ The marked increase in D-dimer levels and thrombocytopenia may suggest a similar coagulation derangement between COVID-19 and disseminated intravascular coagulation. However, some coagulation parameters in COVID-19 differ from those observed in disseminated intravascular coagulation. Indeed, elevated fibrinogen levels and factor VIII activity suggest no high consumption of clotting factors in COVID-19.³⁰

The endothelial glycocalyx (eGC) is another important factor in the pathogenesis of COVID-19 endothelial dysfunction. This complex network structure, of a thickness up to 3 μm, consists of proteoglycans, heparan sulfate, chondroitin sulfate and highly sulfated glycosaminoglycans. The eGC damage plays a key role in the membrane permeability during infections, as it increases leukocyte recruitment, barrier disruption and the development of end-organ complications, especially in the lungs and kidneys. This process involves endo-β-glucuronidases, which destroy the glycocalyx on the cell surface by acting on the glycosaminoglycans hyaluronan (HA) and heparan sulfate chains. Thus, the “cytokine storm” in COVID-19 leads to abnormal degradation of the endothelial glycocalyx, further resulting in endothelial dysfunction determined by the action of HA fragments.^31,32

Arterial Stiffness

Causes and Consequences of Arterial Stiffness

Elastic properties of the aorta provide the Windkessel effect, thus maintaining a stable blood flow to distal organs throughout the cardiac cycle.³³ Ageing and other cardiovascular risk factors, including hypertension, metabolic diseases, chronic kidney disease, smoking, and sleep disturbances, contribute to the progressive stiffening of the aorta. Previous reviews have extensively described the pathophysiological mechanisms involved in this process. They are related to 1) dysfunction of different types of vascular cells (eg, endothelial cells, vascular smooth muscle cells), 2) changes in extracellular matrix composition (eg, elastin fragmentation, enhanced collagen production), and 3) altered shear stress, and 4) increased inflammation and oxidative stress.^34–37 Thus, an increased arterial stiffness deteriorates the mechanics of the aorta. Moreover, an increase in systolic and pulse pressure (PP) can further aggravate arterial stiffening and contribute to 1) heart failure development and 2) damage of the distal microcirculation.^33,36,38

A reliable measure of arterial stiffness might be the assessment of pulse wave velocity (PWV). PWV represents the speed of the pressure wave traveling along the arterial system, which is increased in stiffer arteries. Carrying carotid-femoral pulse wave velocity (cfPWV) is the gold standard because it predicts cardiovascular events.^39–42 Although cfPWV reflects the large elastic artery stiffness, brachial-ankle pulse wave velocity (baPWV) is partly determined by peripheral artery stiffness. Other less frequently used techniques include the direct measurement of arterial distensibility and calculation of stiffness-related parameters such as augmentation index (based on pulse wave reflection) and ambulatory arterial stiffness index.⁴³

Overall, progressive stiffening of the aorta contributes to cardiovascular disease development and is considered an independent predictor of mortality.^39,42 Due to these major implications for cardiovascular health, it is pivotal to demonstrate and understand the acute and long-term consequences of COVID-19 infection on arterial stiffness.

Effect of COVID-19 Infection on Arterial Stiffness

During the acute phase of the SARS-CoV-2 infection, increases in measures of arterial stiffness have been described.⁴⁴ For instance, a higher cfPWV and baPWV were detected in a study comparing twenty-two acutely ill patients with and without COVID-19.⁴⁵ Ratchford et al showed that eleven young adults had a greater cfPWV 3–4 weeks following SARS-CoV-2 infection than healthy controls. The same study reported a significantly lower brachial artery flow-mediated dilation (FMD), suggesting an impaired vascular function.⁴⁶ Szeghy et al reported higher carotid stiffness and Young’s modulus in fifteen young adults who recovered from COVID-19 compared with healthy control adults. In addition, a greater aortic augmentation index was observed within the same patient population, which suggests aortic stiffening.⁴⁷ Interestingly, the severity of the infection seemed to be positively correlated with arterial stiffness. Moderate and severe COVID-19 patients had significantly elevated arterial stiffness compared to mild COVID-19 patients as measured by cfPWV and aortic augmentation index.⁴⁸ Thus, during the acute phase of COVID-19, arterial stiffness seems to be increased, although these results need to be interpreted with caution due to the limited number of included patients.

Since arterial stiffness is a major risk factor for cardiovascular disease development, it is important to determine whether the acute increase in stiffness during COVID-19 infection persists over a longer period of time. For this reason, several studies aimed to determine the long-term consequences of COVID-19 on vascular health.

In young adults, the reported acute effects on arterial stiffness and vascular function seem transient since no difference in cfPWV was observed in sixteen subjects beyond 4 weeks after diagnosis. However, peripheral vascular function remained impaired in patients who were still symptomatic.⁴⁹ Furthermore, in a 6-month follow-up study, cfPWV significantly declined after 4 months and eventually reached levels of the healthy control group.^46,50 The changes in cfPWV were correlated to mean arterial pressure fluctuations.⁵⁰ Given that PWV is highly dependent on blood pressure (BP) levels, PWV values will increase with BP rise.⁵¹ Therefore, it might be possible that the initial increase in cfPWV during the acute phase of SARS-CoV-2 infection, and the subsequent decline over time, is related to BP changes rather than vascular wall structural changes. Indeed, cfPWV values did not change over time when corrected for mean arterial pressure.⁵⁰ These findings were confirmed by Nandadeva et al, who showed that ambulatory BP and cfPWV were inversely related with time since the COVID-19 diagnosis (ranging from 3 to 22 weeks) in young adults. However, the correlation between cfPWV and time after diagnosis was still significant after adjustment for BP changes.⁵²

Within a broader patient population, the effects of an initial SARS-CoV-2 infection on arterial stiffness parameters seem to persist for a longer period than reported for young adults. For instance, fifty patients with a positive SARS-CoV-2 PCR test in the last 3 to 6 months showed a decreased aortic strain and aortic distensibility combined with an increased PP and aortic stiffness index.⁵³ In a longitudinal study by Zanoli et al, forty-one COVID-19 patients showed a higher aortic PWV approximately 5 months after the onset of infection. This measure of arterial stiffness significantly decreased but remained higher than in control individuals 1-year post-COVID-19.⁵⁴ The persistence of arterial stiffness was also confirmed by Lambadiari et al, who observed greater cfPWV, central PP, and systolic BP among seventy COVID-19 patients 4 months after diagnosis.⁵⁵ Even after 12 months, central systolic BP remained high, and cfPWV slightly decreased, reaching values between the 4 months studied patients and the control group.⁵⁶ In addition, endothelial and vascular dysfunctions were observed. Interestingly, a 10-fold increase in malondialdehyde (lipid peroxidation marker) was seen in the COVID-19 group 4 months after diagnosis, suggesting an association between COVID-19-related oxidative stress and impaired vascular function.⁵⁵ Even after 1 year of follow-up, endothelial and vascular impairment remained present. However, a significant reduction in malondialdehyde was observed, and levels were still 2-fold higher than healthy controls.⁵⁶ In contrast, another study reported no increase in cfPWV and other cardiovascular risk factors (eg, BP, BMI) in patients 6 months following SARS-CoV-2 infection (n = 101).⁵⁷ Since increases in arterial stiffness were transient,^54,56 conflicting findings may be related to different timeframes after infection, ranging between 4 and 8 months.⁵⁷ Overall, several studies have reported the effects of SARS-CoV-2 infection on arterial stiffness-related parameters, which gradually decline over time but persist in some patient populations until 1 year after infection.

One of the main mechanisms for the effects of SARS-CoV-2 infection on arterial stiffness is endothelial dysfunction, resulting from increased vascular inflammation and oxidative stress. A dysfunctional endothelium is associated with vasoconstriction, which increases arterial stiffness partly because of the reduced nitric oxide availability.³⁴ However, increased stiffness can also induce further endothelial damage, resulting in a vicious cycle that can lead to long-term consequences (Figure 2).³⁴ Besides endothelial dysfunction, vascular inflammation and oxidative stress are also known to induce the synthesis and activation of matrix metalloproteinases (MMPs). Several studies have reported increased serum or plasma levels of MMP-9 during the acute phase of COVID-19,^58–60 which were normalized 3 months after diagnosis.⁶¹ However, tissue inhibitor of metalloproteinases 2 (TIMP-2) levels, an inhibitor of MMP-9 activity, remained unchanged.⁶¹ Also, increased circulating levels of MMP-2 and MMP-3 have been documented.^59,62,63 Because MMPs can promote arterial stiffness by degrading elastin and increasing collagen deposition, changes in extracellular matrix composition by this mechanism should not be neglected.⁶⁴

Figure 2.

Overview of COVID-19 related vascular complications. SARS-CoV-2 infection gives rise to enhanced oxidative stress, inflammation and angiotensin II (AngII)-angiotensin II type 1 (AT1) receptor signalling, which ultimately leads to endothelial cell (EC) dysfunction and apoptotic cell death (1). An important consequence of EC dysfunction is the development of arterial stiffness due to impaired nitric oxide bioavailability. Also remodelling of the extracellular matrix, leading to a lower elastin/collagen ratio, contributes to arterial stiffness development (2). The increase in vascular stiffness can further damage ECs, thereby resulting in a vicious cycle. Eventually these pathophysiological mechanisms can drive the development of atherosclerosis, peripheral and coronary artery disease (3). (Created with BioRender.com).

Although acute and chronic effects of COVID-19 on arterial stiffness parameters have been described, many uncertainties remain. For instance, sex-specific effects on arterial stiffness and vascular function could not be investigated with sufficient statistical power due to the small number of included participants in current studies. Also, the influence of psychosocial factors remains elusive. However, the ongoing CARTESIAN study, a longitudinal and multicentre trial with more than 2500 participants would shed light on controversial or purely studied problems.⁶⁵ In addition, unraveling the pathophysiological mechanisms underlying the effects of COVID-19 on arterial stiffness would be desirable in future research to develop adequate therapeutic strategies to reduce cardiovascular complications. In conclusion, endothelial dysfunction and vascular stiffness seem to be the main causal factors for the initiation and progression of atherosclerotic disease by SARS-CoV-2 infection (Figure 2).

Atherosclerotic Diseases and COVID-19

Atherosclerosis, consisting of plaque development in the arterial wall, is a chronic inflammatory disease.^66,67 Activation of different pathophysiological pathways contribute to a self-maintaining inflammatory state,^68–70 including 1) cytokine secretion by leukocytes, endothelial cells, platelets, or mast cells,⁷¹ and 2) subendothelial infiltration and deposition of lipids and their oxidation.⁷² Eventually, vulnerable atherosclerotic plaques can rupture, leading to thrombotic occlusion and complications such as a myocardial infarction or stroke, depending on the artery involved. Severe stenosis of arteries, in the absence of rupture, might also be sufficient to restrict blood flow and induce ischemic complications.⁷³

In the process of SARS-CoV-2 penetration into host cells, one of the substantial roles is played by cholesterol. It is important to note that high cholesterol content at the lipid rafts is significant in increasing viral infectivity. The lipid rafts role is both in the interaction between the ACE2 receptors and S proteins, as well as in process of SARS-CoV-2 endocytosis contribution. The cholesterol presence in the cell membrane and on the viral envelope creates more favorable conditions for SARS-CoV-2 replication; furthermore, it interacts with the coronavirus N-terminal fusion peptide, which in turn ensures the virus penetration into the host cell. In the presence of dyslipidemia, a high ACE2 receptors number in lipid rafts of cells contributes to the SARS-CoV-2 penetration into them. In this process, the cholesterol influence on the SARS-CoV-2 S spike configuration also plays an important role, contributing to an increase in affinity for ACE2 receptors. Thus, hypercholesterolemia is associated with a higher risk of severe COVID-19 outcomes. Moreover, type 2 diabetes mellitus and obesity highly worsen the prognosis of patients with COVID-19.^74,75

COVID-19 may further promote atherogeneses in several ways. Firstly, the exaggerated inflammatory and immune response creates a “cytokine storm”, leading to atherosclerotic plaque progression. Experimental studies demonstrated a positive relationship between high concentrations of pro-inflammatory cytokines (TNF-alpha, IL-6, or IL-1β) and plaque instability or rupture. IL-1β induces an increased expression of additional cytokines, such as IL-6, TNF-alpha, IL-8, or chemokines (eg, MCP-1), with pro-inflammatory effects. It also increases lipid uptake by macrophages and enhances vascular inflammation and plaque instability. In addition, the complement system contributes to the exacerbation of inflammatory responses and atherosclerotic plaque progression. Other pathogenic pathways are closely correlated with atherosclerosis progression and instability, like CD14⁺⁺ CD16⁺ cells activated by atherosclerosis.⁶⁸ Secondly, endothelial dysfunction caused by SARS-CoV-2 infection may also activate the release of prothrombotic factors such as von Willebrand and factor VIII, which favors thromboembolic events. Furthermore, the expression of adhesion molecules is upregulated, resulting in leukocyte recruitment and enhanced vascular inflammation. All these mechanisms are reciprocally reinforced, leading to the perpetuation of proinflammatory and prothrombotic states. In addition, due to impaired nitric oxide synthesis, arterial stiffening might occur. All these aspects can contribute to atherosclerotic plaque instability, including a higher risk of rupture and acute vascular events.^71,73

Conversely, pre-existing atherosclerosis can also affect COVID-19 severity. Inflammatory signaling pathways activated in atherosclerosis trigger cytokine and chemokine release, contributing to a pro-inflammatory state, coagulation disorders, and the consecutive activation of innate and adaptive immunity. This inflammatory state of the arterial wall represents the ideal hosting area for SARS-CoV-2 replication. A study using HEK293T cells showed that loading these cells with cholesterol, resulted in an increased endocytosis and infectivity of SARS-CoV-2. A possible explanation could be that cholesterol traffics ACE2 to the entry site of the virus, thereby facilitating endocytosis. Thus, high cellular cholesterol levels, as observed in patients with atherosclerosis, promote viral replication, resulting in a more severe clinical presentation of COVID-19.⁷⁶ Moreover, the increased SARS-CoV-2 infectivity favors immune system overactivation, further promoting atherogenesis and creating a vicious cycle.⁶⁸ Also, in humans, the link between cardiovascular disease (CVD) and COVID-19 has been investigated. A systematic review of 72 studies including 3470 COVID-19 patients showed the presence of CVD and hypertension in 8.3% and 13.3%, respectively.⁷⁷ These comorbidities have been found to worsen the prognosis,⁷⁸ with morbidity being the highest (10.5%) for patients with pre-existing cardiovascular conditions.⁷⁹

Atherosclerosis is the main underlying pathophysiological mechanism causing coronary artery disease (CAD) and peripheral artery disease (PAD). It the context of CAD, plaque has accumulated in coronary arteries, which supply blood to the heart. If peripheral arteries (mainly in the legs) are affected by atherosclerosis, this is referred to as PAD. Both conditions have different symptoms and complications, and can be affected by COVID-19, as discussed below.

Coronary Artery Disease

Coronary artery disease (CAD) is the leading cause of death worldwide. More than 80% of sudden deaths are caused by atherosclerotic CAD.⁸⁰ Modifiable risk factors associated with CAD include diabetes mellitus, hypertension, smoking, hyperlipidemia, obesity, and psychosocial stress.^81,82 In addition, family history is recognized as a non-modifiable risk factor for CAD.⁸³

Due to the COVID-19 pandemic, many scheduled appointments and preventive consultations had to be canceled or postponed. Therefore, many CAD patients were exposed to an increased risk of coronary events.^83,84 Clinical data showed that although hospital admissions for acute myocardial infarction decreased since the COVID-19 outbreak, the cases were more severe. Indeed, higher troponin levels, increased mortality rate, major cardiac complications, and delays from symptoms onset to first medical contact were noticed. The delay in seeking medical treatment was associated with the inertia of 1) health services to treat morbidities unrelated to COVID-19 and 2) patients to visit medical settings because of the potential exposure to SARS-CoV-2 infection.⁸⁵ In addition, it has been reported that patients with severe COVID-19 have a proportionally higher incidence of CAD and are more likely to die while hospitalized than patients without COVID-19.^1,86,87 Some studies proposed the association between inflammation and changes in hemodynamics during COVID-19 with an increased risk of plaque rupture in CAD patients.^79,88–90 Others emphasized the pro-coagulatory COVID-19 effect.⁹¹ Similar findings were obtained by postmortem examinations of COVID-19 patients.⁹² Furthermore, a sedentary lifestyle during the COVID-19 pandemic, because of lockdowns and social distancing rules, contributed to CAD development.⁹³ The above-mentioned emerging problems emphasize the need for detailed and rigorous cardiovascular assessment and treatment in patients with COVID-19.

Pathophysiology

There are at least five pathophysiological mechanisms identified that affect the myocardium in COVID-19 patients: (1) sepsis; (2) lung injury; (3) respiratory failure as a result of severe physiological strain;⁹⁴ (4) type I myocardial infarction secondary to the rupture of atherosclerotic plaque and (5) type II myocardial infarction due to a mismatch between oxygen demand and supply.⁹⁵ The former could be caused by several COVID-19 related mechanisms, including reduced myocardial perfusion due to local coronary atherosclerosis, endothelial dysfunction within the coronary microcirculation, high levels of angiotensin II causing severe systemic hypertension and vasoconstriction leading to hypoxia due to acute respiratory distress syndrome (ARDS) or pulmonary vascular thrombosis. In addition, severe ‘cytokine storms’ (eg, IL-6, IL-7, IL-22, IL-17) have been described during the SARS-CoV-2 infection.^96–98 Particularly, higher plasma concentrations of IL-6 were detected in severe COVID-19 patients and linked to increased mortality.⁸⁶ Several studies have established the link between “cytokine storms” and myocardial damage.^99–101 Interestingly, inflammatory cytokine expression is increased in the epicardial adipose tissue of patients with CAD.^102,103

Diagnosis

Current guidelines for chronic coronary syndrome diagnosis recommend starting with an assessment of the CAD pretest probability, which is based upon patient history, examination, and basic tests such as an electrocardiogram. Patients with a pretest probability score >85% require no further noninvasive testing to be diagnosed with CAD. Instead, they can undergo invasive coronary angiography to gauge the risk level and to develop an appropriate management plan. Patients with a score <15% are considered low risk, and the diagnosis of CAD can be safely excluded. However, a coronary computed tomography angiography can still provide useful information to exclude CAD.¹⁰⁴ Patients with COVID-19 might experience different cardiac events, such as arrhythmias, myocardial damage, and cardiac arrest, complicating CAD diagnosis.^1,105 Moreover, cardiac manifestations can be the initial symptoms in some patients with COVID-19.¹⁰⁶

Several biomarkers are associated with myocardial injury during COVID-19 infection.^107,108 Myocardial injuries associated with COVID-19 result in elevated levels of high-sensitivity cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP).¹⁰⁹ High cTnI levels correlate with the severity of the disease.¹¹⁰ Furthermore, elevated levels of cTnI correlate with viral load, suggesting it induces cardiac injury, likely through plaque rupture or intracoronary thrombus formation.^1,111 Similarly, a positive correlation between cTnI elevation and C-reactive protein or NT-proBNP suggests a close relationship between CAD and the extent of inflammation or ventricular impairment.^86,88 Alternatively, many patients with COVID-19 have detectable levels of cTnI and no evidence of CAD as measured by coronary angiography.¹¹² Thus, the diagnosis of cardiac injury cannot be solely based on cardiac biomarkers and needs to consider other examinations, such as an electrocardiogram and imaging techniques.¹¹³ Moreover, it was hypothesized that the up‐regulation of microRNAs (eg, miR‐21, miR‐155, miR‐208a, and miR‐499) in COVID‐19 survivors might better refine myocardial damage compared to markers like high-sensitive troponin. MicroRNAs can be useful in evaluating the long‐term cardiovascular consequences of COVID-19.^114–116

Treatment

The current CAD management mainly relies on educating the general population on modifiable risk factors for atherosclerosis and how to prevent the disease through lifestyle changes. Unfortunately, quarantine and other social distancing measures during the COVID-19 pandemic harmed the quality of care and disease outcome in CAD patients due to a more sedentary lifestyle, reduced physical activity, postponed medical visits and reduced adherence to drug treatment.¹¹⁷

For CAD patients, drug treatment includes antiplatelet agents, statins, β-blockers, and angiotensin-converting enzyme inhibitors. To prevent thrombotic complications, treatment protocols in COVID-19 and CAD overlap to some extent. For example, hospitalized adults with COVID‐19 may receive thromboprophylaxis based on venous thromboembolism risk scores and D-dimer levels. The recommended prophylaxis is daily treatment with low‐molecular‐weight heparins.^118,119 Although endothelial dysfunction and increased platelet reactivity are common features of CAD and COVID-19 infection, current data is inconsistent regarding the antiplatelet agents benefits in the coronavirus infectious disease progression. In fact, prior chronic treatment with aspirin was found to induce a possible increased risk of hospitalization rates in COVID-19 patients, without any impact on intermediate COVID-19 outcomes (intensive care unit admission, need for intubation) or the all-cause mortality.¹²⁰

Statin treatment showed a beneficial effect on the cardiac vasculature in patients with COVID-19.¹²¹ Interference with main pathogenic viral mechanisms (endothelial activation, release of proinflammatory cytokines, regulation of surface cell expression of ACE2) is considered a key determinant in interpreting the anti-thrombotic and anti-inflammatory effects associated with the administration of statins.¹²² In addition, statin use was shown to be associated with reduction of the risk of intensive care unit admission and lower mortality in COVID-19 patients.^123–125 Another study has shown that older adults on statin therapy have a higher chance of developing asymptomatic COVID-19 as opposed to a symptomatic form of the disease.^126,127 Although extensive research pleads in favor of statin administration (in both pre-hospital and in-hospital settings) in COVID-19 patients, several uncharted findings are yet to be defined (a proven causal relationship between the use of statins and the beneficial effects, type of statins that provide better protection, role of drug interaction, impact of pre-existing comorbidities).^125,128

Many controversies surrounded the negative impact that ACE2 inhibitors or angiotensin receptor blockers (ARBs) might have on SARS-CoV-2 infections, primarily because these agents increase the expression of ACE2 receptors, promoting SARS-CoV-2 entry into the cell.¹²⁹ Nevertheless, this theory was wrong, and RAS blockers showed a protective effect through different mechanisms.¹³⁰

Analyzing data of the Lean European Open Survey on SARS-CoV-2 (LEOSS) registry including 1946 COVID-19 patients with cardiovascular comorbidities revealed that ARBs intake was associated with a significantly lower incidence in overall mortality compared to patients treated with ACE inhibitors or patients who received neither an ACE inhibitor nor an ARB. The protective effects of ARBs seem to involve the limitation of inflammatory disease progression and thrombogenic activation, both variables representing in fact potentially aggravating conditions for the COVID-19 infection evolution.^131,132

Potential benefits of beta blockers in COVID-19 treatment should be related with the antagonist effect over the increased circulating catecholamine levels (by both endogenous and possible iatrogenic mechanism – nebulizers with beta 2 agonists and/or intravenous norepinephrine in septic shock associated with SARS-CoV-2 infection), as well as providing cytokine blockade and effective management of sympathetic storm. In addition, beta blockers may be responsible for down-regulating the expression of ACE2 surface receptors, thus limiting the attachment and viral entry into the host cells.^133,134

Treatment in COVID-19 patients aims to suppress viral replication and reduce the excessive immune response. Anti-inflammatory therapies are found to reduce vascular impairment in COVID-19 patients. Some studies have described reduced endothelial impairment with the administration of tumor necrosis factor-alpha inhibitors¹³⁵ or anti-IL-6 receptor antibodies.¹³⁶ Antiviral therapies have been used extensively during this pandemic and have been shown to reduce viral load and improve symptoms significantly.^137–139

In addition, some studies have shown positive outcomes in improving vascular function through lifestyle changes and therapies. Recommendations to maintain a healthy lifestyle and to manage chronic medical conditions are highlighted in the guideline regarding the management of cardiovascular disease in association with COVID-19. It is admitted that CAD is a condition which may lead to a more severe course of SARS-CoV-2 infection.¹⁴⁰ Actually, the efficacy regarding reducing cardiovascular events in patients diagnosed with CAD was observed in research in which intervention was focused on multiple lifestyle factors: dietary pattern (increased fruit and vegetable intake, decrease fat intake), physical activity, overweight, smoking, alcohol consumption, perceived stress, sleep quality and adherence to medications.^141,142 The assessment of the association between lifestyle risk factors (physical inactivity, smoking, overweight/obesity) and incidence of COVID-19-cases hospitalized in a UK population-based cohort study concluded that patients with unhealthy behaviours had 4-fold higher risk for severe infection with SARS-CoV-2.¹⁴³ Based on positive result regarding the improvement in lifestyle habits in patients with CAD, in COVID-19 era, the lifestyle-related interventions should be priority for the secondary CAD prevention.¹⁴⁴

Peripheral Artery Disease

Peripheral artery disease (PAD) is a common circulatory problem that affects more than 22 million individuals worldwide, particularly the elderly.¹⁴⁵ It is a chronic arterial occlusive disease, mainly caused by the progression of atherosclerosis, and most frequently affects the lower limbs. However, it can affect any extra-coronary or cerebral artery.^146,147 Smoking, obesity, diabetes mellitus, hypertension and a sedentary lifestyle represent the pivotal modifiable risk factors for PAD.²² The clinical presentation of PAD varies from no symptoms to intermittent claudication or critical limb ischemia. It also affects the functional status, leading to reduced quality of life.^146,147 The COVID-19 pandemic, the lockdowns, and social distancing together or separately 1) limited PAD diagnosis, 2) delayed its treatment, and 3) increased the prevalence of the disease.^93,148,149

The relationship between PAD and COVID-19 and whether its co-prevalence leads to worse outcomes is still under investigation. Nevertheless, PAD patients with COVID-19 have a 40% greater rate of major adverse cardiovascular events compared to PAD patients without COVID-19.¹⁵⁰ Furthermore, acute limb ischemia can be a complication for hospitalized patients with severe COVID-19 and patients with mild symptoms of COVID-19. In addition, acute limb ischemia can occur with ischemic symptoms in other vascular beds and in connection with vaccine-induced immune thrombocytopenia and thrombosis (VITT).^151,152 Finally, COVID-19 patients with hypertension and diabetes mellitus are more vulnerable to lower extremity complications resulting in advanced PAD (gangrene or ulcerations).¹⁵³

Pathophysiology

As described above, SARS-CoV-2 can infect cells by attaching to the ACE2 receptor. This infection causes inflammation, endothelial dysfunction, and promotes a prothrombotic state. In addition, endothelial dysfunction leads to NO deficiency, accompanied by increased oxidative stress, which is known to worsen PAD progression. Finally, platelets and coagulation factors can be activated by hypoxia in PAD patients, resulting in a hypercoagulable state. Inhibition of endogenous anticoagulant proteins and an increase in plasminogen activator inhibitor I and tissue factor were involved.^148,154,155

Diagnosis

The diagnosis of PAD is based upon 1) medical history (particularly suggestive symptoms for PAD), 2) physical examination, 3) ankle-brachial index (ie, <0.9 indicates obstructive disease and >1.4 exhibits arterial stiffness), and 4) toe-brachial index in elderly, diabetic or chronic kidney disease patients, as well as in patients with chronic limb-threatening ischemia, as ankle-brachial index can be falsely elevated in these patient groups. Also, imaging techniques can be used, such as duplex ultrasound (screening and diagnostic tool) or a computed tomography angiography.^146,156

The following circulatory biomarkers are related to disease progression and can be evaluated in PAD patients during follow-up: C-reactive protein, IL-6, fibrinogen, D-dimers, neopterin, and pentraxin-3.^157,158 Importantly, different clinical studies have also reported increases in some of these biomarkers in COVID-19 patients, such as C-reactive protein, IL-6, fibrinogen, and D-dimer. These measures have also been tested as prognostic markers of future thrombotic events.¹⁵⁹ Moreover, studies in COVID-19 patients who experienced claudication symptoms showed an increased PAD diagnosis with computed tomography angiography and elevated clot risk.²²

Treatment

The primary therapeutic goal for symptomatic and asymptomatic PAD patients is to minimize cardiovascular risk and improve quality of life. For example, improving functional status is an additional objective in symptomatic patients. In patients with critical limb ischemia, the aim is to reduce mortality and to prevent limb amputation and restore mobility.^{154,160–162} Lifestyle modifications by increasing physical activity, adopting healthy eating habits, and managing comorbidities, form the first-line therapy.¹⁶³ In symptomatic patients, structured exercise therapy can reduce claudication.¹⁵⁴ Physical exercise can be performed at home and may benefit PAD patients in the COVID-19 era.^145,164 COVID-19 patients with comorbidities should be screened for pre-existing PAD. Additionally, as it seems to reduce mortality, COVID-19 patients with high D-dimers should receive anticoagulation therapy (low molecular weight heparin) for clot prevention.¹⁵⁹ Statins reduce cardiovascular events and mortality in symptomatic and asymptomatic PAD patients. As reported above, their use is associated with lower clinical symptoms and mortality in COVID-19 patients.^123,126 The standard approach to control comorbidities should be applied according to the guidelines.^146,154,165

COVID-19 Vaccines

Vaccines are an important tool in fighting against COVID-19 and are especially effective in prevention of severe forms of the disease and of complications. Acknowledging this perspective, several vaccines were approved (eg, Pfizer-BioNtech, Moderna, Jenssen, Oxford-AstraZeneca, Sinopharm BBIBP-CorV, etc.) demonstrating significant efficacy and safety without any major side effects.^166–168

Minor side effects (eg, local reaction at the injection site, headache, muscle pain) and clinically important adverse effects (eg, myocarditis, pericarditis, and thrombotic events) were reported following the COVID-19 vaccine. In addition, acute coronary syndromes, hypertension, and arrhythmias also have been reported as very rare cardiovascular side effects, without finally confirmed association.¹⁶⁹

Acute Coronary Syndromes

A study performed in Denmark and Norway found that one dose of Astra Zeneca vaccine was linked with excess event rate of 0.6 per 100 000 vaccinations for acute myocardial infarction but without statistical significance.¹⁷⁰ An analysis of VigiBase database of World Health Organization demonstrated 13 patients (0.27% of all cardiovascular complications) with angina pectoris, 32 (0.66%) patients with myocardial infarction and 16 (0.33%) patients with acute myocardial infarction.¹⁷¹

It should be emphasized that a proportion of patients receiving a COVID-19 vaccination will be prone to develop, by chance, acute myocardial infarction due to the baseline risk of acute CAD worldwide.¹⁷⁰ In a Phase 3 trial (randomized observer-blinded, placebo-controlled) conducted in over 99 centers in the United States with over 30 thousand volunteers, the proportion of myocardial infarction was similar between patients that received or not the mRNA-1273 vaccine (3 cases of myocardial infarction in placebo group and 5 cases in vaccine).¹⁷² A retrospective study of 231 037 patients (168 310 fully vaccinated and 62,727 non-vaccinated) suffering from COVID-19 reveal that fully vaccinated patients had a lower probability of acute myocardial infarction (HR 0.48) compared with non-vaccinated people after a follow up of 84 days.¹⁷³ These results are important given the result that showed an increased risk of myocardial infarction after infection with SARS-CoV-2.¹⁷⁴ A recent large study intended to assess the short-term risk of severe cardiovascular events (MI, pulmonary embolism, stroke) after the COVID-19 vaccine was performed in France on 46.5 million adults younger than 75 years. No association was found between Moderna or Pfizer–BioNTech vaccine and MI. However, the first dose of the Oxford-AstraZeneca vaccine was associated with MI in the second week after the vaccination. An association between the Janssen vaccine and MI in the second week after a single dose could not be ruled out.¹⁷⁵

Although no association between the COVID-19 vaccine and MI can be determined, multiple putative pathophysiological mechanisms for the association of and vaccination have been proposed:

• A Kounis syndrome development representing a discrete form of infarction based on exaggerated immune system activation.^176,177

• Vaccine-induced thrombotic thrombocytopenia. It is assumed that the mechanism behind these changes is an immune-mediated mechanism, similar to heparin-induced thrombocytopenia.¹⁷⁸

• Demand-supply mismatch mediated by the stress of getting the vaccine, especially in the elderly or individuals with comorbidities.¹⁶⁹

• Myocarditis.¹⁶⁹

Other possible vaccination adverse effects were Takotsubo cardiomyopathy and myocardial infarction with non-obstructive coronary arteries (MINOCA). A systematic review of case reports described four cases of Takotsubo cardiomyopathy with symptoms developing between 15 minutes to 4 days after vaccination and a case of MINOCA, which occurred 2 hours after vaccination with the first dose of BNT162b2 vaccine.¹⁷⁹

Based on the available data the relationship between myocardial infarction and vaccination is doubtful, and no causal effect between vaccination and MI was proven.¹⁶⁹ It is worth also to strongly emphasize that those not finally proved adverse effects cannot underweight the large benefit of vaccination to prevent CVD complications in COVID-19 patients.

Myocarditis and Pericarditis

After vaccination with various vaccine (measles, mumps, rubella, varicella zoster virus, yellow fever, or smallpox) rare cases of myocarditis have been reported. Similarly, rare cases of myopericarditis have been reported after the second dose of COVID-19 vaccine.¹⁸⁰

A study performed in Israel compared 884,000 vaccinated cases with 884,000 unvaccinated subjects (controls). Also, about 173,000 positive cases for COVID-19 were compared with the same number of negative subjects. The conclusion was that COVID-19 disease among unvaccinated people is responsible for much greater increase in cases of myocarditis and pericarditis compared with vaccinated people (the odds ratio was 1.27 following Pfizer vaccine administration as opposed to 5.39 for patients positive with SARS-CoV-2).¹⁸¹ The cases of myocarditis associated with vaccination were concentrated in the first 5–7 days after the second dose, the highest incidence being found in males with age between 16 and 39.¹⁸² The analysis of Vaccine Adverse Event Reporting System (VAERS database) which included 354,100,845 total vaccinations with Pfizer-BioNTech or Moderna found 1626 cases of myocarditis (0.8 per 100,000) diagnosis establish according to “Centre for Disease Control” criteria. The peak incidence of myocarditis occurred between 15 and 17 years old for Pfizer and between 18 and 23 years for Moderna vaccine.¹⁸³

A meta-analysis of 22 studies with a total of 405,272,721 vaccine doses showed that the incidence of myocarditis and pericarditis tends to be lower after COVID-19 vaccines compared with non-COVID-19 vaccines (eg, smallpox vaccine) with an incidence of 1.6 vs 5.6 cases/100,000 but without statistical significance. Also, the study found a higher incidence of myocarditis and pericarditis after mRNA vaccines than with non-mRNA vaccines and a progressively higher incidence of myocarditis with decreasing age.¹⁸⁴

There are a few potential mechanisms proposed for pathophysiology of COVID-19 vaccine-related myocarditis and myopericarditis: (1) in patients with preexisting dysregulated pathways vaccination may trigger an immune-mediated adverse response; (2) patients with susceptibility to myocarditis have elevated heart-reactive autoantibodies that could attack cardiac myocyte after vaccination.¹⁸⁵

Diagnosis of myocarditis is made clinically (patients presents with chest pain, dyspnea, tachipnea, palpitations, rarely headache, cough) associated with ECG changes (diffuse ST-segment elevation, nonspecific ST changes, T-wave inversions), elevated cardiac markers (troponin, BNP, NT-proBNP) echocardiography (left ventricular systolic dysfunction, pericardial effusion, left ventricular dilatation) and cMRI (impaired regional and global ventricular function, and myocardial edema ± late gadolinium enhancement based on T2-weighted imaging or T2 mapping).^185,186

There are very few reports of myocardial biopsy in patients with myocarditis and have shown inflammatory infiltrates within the myocardium associated with myocyte damage/necrosis of nonischemic origin. Different histologic patterns of myocarditis are represented by lymphocytic myocarditis, eosinophilic myocarditis, or healing myocarditis.¹⁸⁶

The treatment for myocarditis is supportive and includes treatment for symptoms, treatment for arrhythmias and adequate perfusion. Nonsteroidal anti-inflammatory drugs and colchicine are indicated, and glucocorticoids and immunoglobulins are given to the patients with poor response to reduce the immune reaction.^187,188

Reported cases have shown a benign course of the disease and favorable short-term outcomes with only 2 deaths reported.¹⁸⁵ The long-term implications of this side effect for the patients are unknown but this small risk is outweighed by the benefit of vaccination against COVID-19.¹⁸⁰

The benefits of vaccination over non-vaccination in terms of prevented hospitalizations and serious COVID-19 complications remain undisputable. In patients that develop these cardiovascular side effects of the vaccine, the complications are effectively treated, and quick recovery of the patients are reported. Compared with the total number of vaccinated people, the incidence of cardiovascular adverse effects remains very rare, thus confirming the fact that the benefits of vaccination outweigh the risks.^189,190

Conclusions

The bi-directional relationship between atherosclerosis and COVID-19 is accompanied by poor prognosis. The immune response hyperactivation due to SARS-CoV-2 infection causes an increased secretion of cytokines (so-called “cytokine storm”), endothelial dysfunction, and arterial stiffness, which promotes the development of atherosclerosis. Also, due to the COVID-19 pandemic, access to healthcare amenities was reduced, resulting in increased morbidity and mortality in patients at risk. Furthermore, as lockdown measures were largely adopted worldwide, the sedentary lifestyle and the increased consumption of processed nutrients or unhealthy food increased. However, the experience gained in the COVID-19 pandemic and the new methods of patients’ approaching have helped the medical system to overcome this crisis and will certainly help in the case of new possible epidemics.

Disclosure

Annabelle Shor, Raluca Ecaterina Haliga, Viviana Onofrei Aursulesei and Oana Sirbu have the same contribution as the first author for this study. The authors report no conflicts of interest in this work.